vs

Side-by-side financial comparison of agilon health, inc. (AGL) and Calumet, Inc. (CLMT). Click either name above to swap in a different company.

agilon health, inc. is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.5× Calumet, Inc.). Calumet, Inc. runs the higher net margin — -3.6% vs -12.0%, a 8.4% gap on every dollar of revenue. Calumet, Inc. produced more free cash flow last quarter ($103.8M vs $-23.5M).

agilon health, inc. is a U.S.-based healthcare company partnering with primary care providers to deliver value-based care solutions mainly for senior Medicare beneficiaries. It offers administrative support, clinical tools and risk management frameworks to help physicians improve patient outcomes and cut care costs, operating across over 20 U.S. states.

Calumet, Inc. is a U.S.-headquartered specialty products firm that manufactures and distributes high-value hydrocarbon and specialty chemical products. Its offerings include specialty oils, lubricants, waxes, and renewable fuel solutions, serving industrial, consumer, and transportation segments across North America.

AGL vs CLMT — Head-to-Head

Bigger by revenue
AGL
AGL
1.5× larger
AGL
$1.6B
$1.0B
CLMT
Higher net margin
CLMT
CLMT
8.4% more per $
CLMT
-3.6%
-12.0%
AGL
More free cash flow
CLMT
CLMT
$127.3M more FCF
CLMT
$103.8M
$-23.5M
AGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGL
AGL
CLMT
CLMT
Revenue
$1.6B
$1.0B
Net Profit
$-188.9M
$-37.3M
Gross Margin
-0.3%
Operating Margin
-12.3%
-6.2%
Net Margin
-12.0%
-3.6%
Revenue YoY
3.1%
Net Profit YoY
-78.5%
EPS (diluted)
$-0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGL
AGL
CLMT
CLMT
Q4 25
$1.6B
$1.0B
Q3 25
$1.4B
$1.1B
Q2 25
$1.4B
$1.0B
Q1 25
$1.5B
$993.9M
Q4 24
$1.5B
Q3 24
$1.5B
$1.1B
Q2 24
$1.5B
$1.1B
Q1 24
$1.6B
Net Profit
AGL
AGL
CLMT
CLMT
Q4 25
$-188.9M
$-37.3M
Q3 25
$-110.2M
$313.4M
Q2 25
$-104.4M
$-147.9M
Q1 25
$12.1M
$-162.0M
Q4 24
$-105.8M
Q3 24
$-117.6M
$-100.6M
Q2 24
$-30.7M
$-39.1M
Q1 24
$-6.1M
Gross Margin
AGL
AGL
CLMT
CLMT
Q4 25
-0.3%
Q3 25
34.7%
Q2 25
-4.2%
Q1 25
-8.2%
Q4 24
Q3 24
0.4%
Q2 24
5.6%
Q1 24
Operating Margin
AGL
AGL
CLMT
CLMT
Q4 25
-12.3%
-6.2%
Q3 25
-9.1%
30.0%
Q2 25
-8.3%
-9.8%
Q1 25
-1.4%
-4.9%
Q4 24
-7.1%
Q3 24
-9.2%
-5.2%
Q2 24
-2.9%
0.5%
Q1 24
-0.4%
Net Margin
AGL
AGL
CLMT
CLMT
Q4 25
-12.0%
-3.6%
Q3 25
-7.7%
29.1%
Q2 25
-7.5%
-14.4%
Q1 25
0.8%
-16.3%
Q4 24
-6.9%
Q3 24
-8.1%
-9.1%
Q2 24
-2.1%
-3.4%
Q1 24
-0.4%
EPS (diluted)
AGL
AGL
CLMT
CLMT
Q4 25
$-0.43
Q3 25
$3.61
Q2 25
$-1.70
Q1 25
$-1.87
Q4 24
Q3 24
$-1.18
Q2 24
$-0.48
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGL
AGL
CLMT
CLMT
Cash + ST InvestmentsLiquidity on hand
$173.7M
$125.1M
Total DebtLower is stronger
$35.0M
$2.1B
Stockholders' EquityBook value
$126.7M
$-732.7M
Total Assets
$1.3B
$2.7B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGL
AGL
CLMT
CLMT
Q4 25
$173.7M
$125.1M
Q3 25
$171.7M
$94.6M
Q2 25
$171.4M
$110.6M
Q1 25
$136.9M
$123.4M
Q4 24
$188.2M
Q3 24
$148.2M
$34.6M
Q2 24
$109.5M
$7.0M
Q1 24
$111.7M
Total Debt
AGL
AGL
CLMT
CLMT
Q4 25
$35.0M
$2.1B
Q3 25
$2.1B
Q2 25
$2.1B
Q1 25
$2.3B
Q4 24
Q3 24
$1.7B
Q2 24
Q1 24
Stockholders' Equity
AGL
AGL
CLMT
CLMT
Q4 25
$126.7M
$-732.7M
Q3 25
$306.1M
$-695.3M
Q2 25
$408.9M
$-1.0B
Q1 25
$500.3M
$-862.3M
Q4 24
$471.0M
Q3 24
$574.9M
$-672.2M
Q2 24
$676.6M
$-566.4M
Q1 24
$689.3M
Total Assets
AGL
AGL
CLMT
CLMT
Q4 25
$1.3B
$2.7B
Q3 25
$1.6B
$2.7B
Q2 25
$1.7B
$2.8B
Q1 25
$1.9B
$2.8B
Q4 24
$1.7B
Q3 24
$2.1B
$2.6B
Q2 24
$2.2B
$100
Q1 24
$2.3B
Debt / Equity
AGL
AGL
CLMT
CLMT
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGL
AGL
CLMT
CLMT
Operating Cash FlowLast quarter
$-20.5M
$116.5M
Free Cash FlowOCF − Capex
$-23.5M
$103.8M
FCF MarginFCF / Revenue
-1.5%
10.0%
Capex IntensityCapex / Revenue
0.2%
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-119.0M
$56.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGL
AGL
CLMT
CLMT
Q4 25
$-20.5M
$116.5M
Q3 25
$-18.2M
$23.5M
Q2 25
$-35.1M
$-1.8M
Q1 25
$-32.0M
$-29.3M
Q4 24
$16.4M
Q3 24
$-7.7M
$-15.5M
Q2 24
$-18.7M
Q1 24
$-47.8M
Free Cash Flow
AGL
AGL
CLMT
CLMT
Q4 25
$-23.5M
$103.8M
Q3 25
$-21.3M
$15.1M
Q2 25
$-38.3M
$-15.4M
Q1 25
$-35.8M
$-46.9M
Q4 24
$13.2M
Q3 24
$-11.2M
$-32.2M
Q2 24
$-22.0M
Q1 24
$-50.9M
FCF Margin
AGL
AGL
CLMT
CLMT
Q4 25
-1.5%
10.0%
Q3 25
-1.5%
1.4%
Q2 25
-2.7%
-1.5%
Q1 25
-2.3%
-4.7%
Q4 24
0.9%
Q3 24
-0.8%
-2.9%
Q2 24
-1.5%
Q1 24
-3.2%
Capex Intensity
AGL
AGL
CLMT
CLMT
Q4 25
0.2%
1.2%
Q3 25
0.2%
0.8%
Q2 25
0.2%
1.3%
Q1 25
0.3%
1.8%
Q4 24
0.2%
Q3 24
0.2%
1.5%
Q2 24
0.2%
2.2%
Q1 24
0.2%
Cash Conversion
AGL
AGL
CLMT
CLMT
Q4 25
Q3 25
0.07×
Q2 25
Q1 25
-2.64×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGL
AGL

Medical Services$1.6B100%
Other Operating$2.5M0%

CLMT
CLMT

Specialty Products And Solutions$675.9M65%
Montana Renewables$294.2M28%
Performance Brands$68.5M7%

Related Comparisons